EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
09 Agosto 2023 - 8:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious eye disorders, today announced that Jay S.
Duker, M.D., President and Chief Executive of EyePoint
Pharmaceuticals will present at the H.C. Wainwright 3rd Annual
Ophthalmology Virtual Conference:
- Company
OverviewDate: Wednesday, August 16th, 2023Time: Available
on-demand at 7:00 a.m. ET
- Sustained Treatment for Wet
AMD Panel DiscussionDate: Wednesday, August 16th,
2023Time: 11:00 a.m. ET
A live webcast and subsequent archived replay of
the panel and the on-demand company overview may be accessed via
the Investors section of the Company website at
www.eyepointpharma.com. The replay will be available for 90 days
after the event.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
company committed to developing and commercializing therapeutics to
help improve the lives of patients with serious eye disorders. The
Company's pipeline leverages its proprietary bioerodible Durasert
E™ technology for sustained intraocular drug delivery including
EYP-1901, an investigational sustained delivery intravitreal
anti-VEGF treatment currently in Phase 2 clinical trials. The
proven Durasert® drug delivery platform has been safely
administered to thousands of patients' eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts. For more information visit
www.eyepointpharma.com.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024